Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ergocalciferol in Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00411294
Recruitment Status : Completed
First Posted : December 13, 2006
Last Update Posted : December 13, 2006
Sponsor:
Information provided by:
Saint Louis VA Medical Center

Brief Summary:
To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4

Condition or disease
Chronic Kidney Disease

Layout table for study information
Study Type : Observational
Observational Model: Defined Population
Time Perspective: Retrospective
Official Title: The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels >70 pg/ml.

Exclusion Criteria:

  • Patients who are on any form of active vitamin treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00411294


Locations
Layout table for location information
United States, Missouri
Saint Louis VA Medical Center
Saint Louis, Missouri, United States, 63104
Sponsors and Collaborators
Saint Louis VA Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Ziyad Al-Aly, M.D. VAMC-Saint Louis
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00411294    
Other Study ID Numbers: ZA-01
First Posted: December 13, 2006    Key Record Dates
Last Update Posted: December 13, 2006
Last Verified: December 2006
Keywords provided by Saint Louis VA Medical Center:
ergocalciferol
chronic kidney disease
secondary hyperparathyroidism
vitamin D deficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency